9 stories mentioning ATAIUpdated 10d ago
Every FINWIRES story that references ATAI, newest first.
AtaiBeckley (ATAI) has an average rating of overweight and mean price target of $11.54, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
AtaiBeckley (ATAI) has an average rating of overweight and mean price target of $11.54, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
AtaiBeckley (ATAI) has an average rating of overweight and mean price target of $12.14, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
AtaiBeckley (ATAI) has an average rating of overweight and mean price target of $12.14, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index rising 1.7% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2%.The iShares Biotechnology ETF (IBB) was down 0.7%.In corporate news, Merck (MRK) shares gained 3% after it said Thursday that the Food and Drug Administration has approved Lipfendra 20 mg tablets as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol, or LDL-C, in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.UnitedHealth (UNH) shares rose 1.7% after it posted higher Q2 adjusted earnings and revenue and raised its 2026 adjusted EPS outlook.AtaiBeckley (ATAI) shares surged 32% after Eli Lilly (LLY) said it agreed to acquire the clinical-stage biopharmaceutical company for up to $3.8 billion. Lilly was up 0.8%.Abbott Laboratories (ABT) lifted its full-year earnings outlook on Thursday as the healthcare firm reported Q2 results above market estimates. Abbott shares jumped past 10%.
Healthcare stocks were higher Thursday afternoon, with the NYSE Healthcare Index rising 1.8% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2%.The iShares Biotechnology ETF (IBB) was down 0.4%.In corporate news, UnitedHealth (UNH) shares rose 3.3% after it posted higher Q2 adjusted earnings and revenue and raised its 2026 adjusted EPS outlook.AtaiBeckley (ATAI) shares surged 33% after Eli Lilly (LLY) said it agreed to acquire the clinical-stage biopharmaceutical company for up to $3.8 billion. Lilly was up 1.3%.Abbott Laboratories (ABT) lifted its full-year earnings outlook on Thursday as the healthcare firm reported Q2 results above market estimates. Abbott shares jumped 11%.
AtaiBeckley (ATAI) shares surged more than 30% on Thursday after Eli Lilly (LLY) said it agreed to acquire the clinical-stage biopharmaceutical company for up to $3.8 billion.The purchase price comprises $2.8 billion in upfront cash and about $1 billion in contingent value rights, the pharmaceutical giant said Thursday.New York-based AtaiBeckley is developing rapid-acting therapies for mental health conditions, with its BPL-003 lead program currently in phase 3 development as an intranasal therapy for treatment-resistant depression.Under the agreement, Eli Lilly will pay $6.75 per share in cash upon closing and up to $2.50 per share in CVRs.The CVR payment includes $1 upon starting a phase 3 trial for VLS-01, a dissolving oral film targeting treatment-resistant depression, within four years of closing and another $1 upon US regulatory approval and Drug Enforcement Administration rescheduling of the drug within seven years. The remaining $0.50 is tied to US regulatory clearance and rescheduling of BPL-003, within five years."Treatment-resistant depression persists even after multiple treatments have failed. Millions of people are still searching for relief and desperately need a therapy that works," Carole Ho, president of Lilly Neuroscience, said in a statement. "Advancing AtaiBeckley's investigational therapies gives us a real chance to change that."Earlier this year, Eli Lilly agreed to acquire Centessa Pharmaceuticals for up to $7.8 billion, Kelonia Therapeutics for up to $7 billion, Orna Therapeutics for up to $2.4 billion, and three vaccine developers, Curevo, Vaccine Company, and LimmaTech Biologics for up to $1.5 billion, $1.55 billion, and $780 million, respectively.In April, the drugmaker raised its full-year outlook and reported better-than-expected first-quarter results. The company's second-quarter results are scheduled for Aug. 5.AtaiBeckley shares rose 33% in recent Thursday trading, while Eli Lilly was up 1.4%.Price: $7.16, Change: $+1.80, Percent Change: +33.49%
Healthcare stocks were rising pre-bell Thursday, with the State Street Health Care Select Sector SPDR ETF (XLV) 1.2% higher and the iShares Biotechnology ETF (IBB) up 0.5%.UnitedHealth Group (UNH) stock was up more than 7% after the company posted higher Q2 adjusted earnings and revenue, and raised its 2026 adjusted EPS outlook.Abbott Laboratories (ABT) shares were up more than 5% after the company reported higher Q2 adjusted earnings and revenue, and raised its 2026 adjusted EPS guidance.Eli Lilly (LLY) has agreed to acquire AtaiBeckley (ATAI) for $2.8 billion in cash plus potential milestone payments of up to $1.0 billion, the companies said. AtaiBeckley stock was up more than 33% pre-bell.
Shares of some psychedelic drug companies gained Friday morning after the US Food and Drug Administration said it was launching regulatory actions to back the development of psychedelic therapies to treat mental illness.Cybin (HELP) shares jumped past 4%, Psyence Biomedical (PBM) shares climbed 7%, and Clearmind Medicine (CMND) shares were up 2.4%.The FDA's move builds on President Donald Trump's recent executive order directing the Department of Health and Human Services to accelerate access to treatments for people with serious mental illness, the FDA said.The drugs have the potential to address mental health diseases like treatment-resistant depression, alcoholism and substance abuse, said FDA Commissioner Marty Makary.The agency said it is issuing national priority vouchers to three companies researching psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone for post-traumatic stress disorder.The agency said it is also allowing an early-phase trial of noribogaine hydrochloride to proceed following an investigational new drug filing. The sponsor is investigating noribogaine to potentially treat alcohol use disorder, the FDA said, adding the move will allow the company developing the new drug, DemeRx NB, to start a phase 1 trial in the US.The agency said it will release final guidance "imminently" to provide recommendations to sponsors developing psychedelic medications.Price: $8.89, Change: $-0.27, Percent Change: -2.90%
